Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in NSCLC Patients with Uncommon EGFR Mutations (Open-label Phase II Single-arm Study)
KCT0003459Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003459.